Moving treatment-free remission into mainstream clinical practice in CML.
about
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemiaTyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.The role of early molecular predictor in transplant-eligible chronic myelogenous leukemia.Minimal Residual Disease Eradication in CML: Does It Really Matter?Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches.The impact of structural biology in medicine illustrated with four case studies.Patient perceptions of treatment-free remission in chronic myeloid leukemia.Are chronic myeloid leukemia patients ready to stop long-term treatment?Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis.Treatment-free remission in patients with chronic myeloid leukemia.Insights into the management of chronic myeloid leukemia in resource-poor settings: a Mexican perspective.Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.The role of the CCN family of proteins in blood cancers.Chronic myeloid leukemia: room for improvement?Research in the heart of hematology: chronic myeloid leukemia 2017.CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients.Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events - is better always good?Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?Similar expression profiles in CD34+ cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.Breastfeeding in Patients with Chronic Myeloid Leukaemia: Case Series with Measurements of Drug Concentrations in Maternal Milk and Literature Review.Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients.Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study.Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CML.Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence.Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysisAllosterische Kinaseinhibitoren
P2860
Q27027369-1AA097B3-1992-4B85-89BB-6F271CD770D6Q30242015-9C41DD63-8726-4A92-9014-13E56CA65285Q33593877-484A63DA-536C-4049-B413-4A60C904BCD3Q33646189-199CF39B-9D6C-4F38-AEC8-CCBB5BB2BB94Q33890580-E84726C4-A436-42F3-801C-5CE5450358EAQ33899734-E1BF8F33-850F-4BE4-A4B6-E310F75EF30CQ37559198-ADC77D77-C506-4139-8615-95AEC8EFF822Q38602633-40316D3B-04DF-4ACA-99AB-31EC39C85DA7Q38684223-DE4CD0A2-B767-4E8B-8510-5B23F754739DQ38698199-42B8E7FA-EAD6-4267-B41A-254DA7788751Q38724708-BDFAA3B3-9314-455F-9AE1-F5C169E13622Q38768659-B628115F-773E-4054-94FF-91E17B6D9142Q38797683-4E9EBAC7-5309-4952-BBD0-873F82862773Q39415339-05925AB1-7409-4151-BA0D-51B6703AAE65Q39423384-EE497C10-9581-4F6B-B3AA-18B9A1E98BFAQ39457369-5DF12953-D677-4DF3-A2FB-408D4BF8BF2BQ40062215-9C4A0098-6762-42B2-AF37-345F5A5E3A46Q41371363-6822ED76-F5CC-41CE-8092-A476016876EEQ42348447-9091C663-164C-4DF0-B22F-6EB418FB41A6Q42361988-36654A8F-F703-4A05-8631-53B0A753B6C9Q47099925-038BA6D6-5ACE-4889-80CD-D6B77BE6150CQ47162210-8C1557AE-A4E4-4851-A489-6DF49F02C14DQ48029208-5BF43297-2B8C-41FA-97FD-5B67B92350B5Q48162932-7E3CB573-CC6D-49B9-A1E4-33A1D27EC7F9Q48310780-FDED8EDD-56BD-4ACD-9738-BE431DAD3474Q48320624-8B1528FF-0DDC-481F-BDF8-206A9903A256Q49888044-EC259808-5395-40CF-A2AC-DAB351926B9BQ50422379-97E75C59-E5CA-462C-8304-4A94B5F14255Q50997822-270E168C-EEFA-48C8-9203-77EAFFCBC327Q52715772-93820BCA-9652-4EDD-A480-EDCCF329AC21Q52816089-3525B68D-97DC-4F87-9C1B-DD6424BB9325Q53703550-ABDFC529-E82A-4E41-AB4A-119D4E1BCE8CQ54110129-66E1EF0F-4FCD-4978-B9E2-90ACDD5584F0Q54119186-A4C3A1AC-70B1-479C-8AAA-F3B3F48DC285Q54981978-B17E9B15-E231-449B-9D6D-15BBC6CAD8DAQ55004578-A771B157-D016-410A-A1F2-981927552887Q55005455-ACF4179F-7E23-4216-8561-774755D26374Q55177555-04F1AB43-2849-44AF-8F48-B676DDBC979FQ57069646-5F2AE8C7-6E15-4FF7-A7D3-42C54C527732Q57902738-3554DC0A-9676-40E2-A1A3-5798CD53F797
P2860
Moving treatment-free remission into mainstream clinical practice in CML.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Moving treatment-free remission into mainstream clinical practice in CML.
@en
Moving treatment-free remission into mainstream clinical practice in CML.
@nl
type
label
Moving treatment-free remission into mainstream clinical practice in CML.
@en
Moving treatment-free remission into mainstream clinical practice in CML.
@nl
prefLabel
Moving treatment-free remission into mainstream clinical practice in CML.
@en
Moving treatment-free remission into mainstream clinical practice in CML.
@nl
P1433
P1476
Moving treatment-free remission into mainstream clinical practice in CML.
@en
P2093
Timothy P Hughes
P356
10.1182/BLOOD-2016-01-694265
P407
P50
P577
2016-03-24T00:00:00Z